C2N Diagnostics expands Alzheimer’s blood testing to South Korea
C2N Diagnostics has partnered with BeauBrain Healthcare to introduce its Precivity portfolio of Alzheimer’s blood tests in South Korea, significantly enhancing diagnostic capabilities for healthcare professionals. The PrecivityAD2 test targets patients aged 50 and older exhibiting mild cognitive impairment or dementia, aiming to detect amyloid plaques—key indicators of Alzheimer’s disease—through a less invasive and more accessible method than traditional amyloid PET imaging.
This development is crucial for the longevity and healthspan field, as it aligns with the growing demand for early and accurate Alzheimer’s diagnoses, particularly with the recent approval of disease-modifying therapies. Research indicates that the PrecivityAD2 test boasts a diagnostic accuracy of 91%, with high sensitivity and specificity compared to PET imaging, potentially transforming clinical management and treatment decisions for patients.
As the landscape of Alzheimer’s diagnostics evolves, this partnership underscores the importance of integrating blood-based biomarkers into routine practice. For a deeper dive into this significant advancement, I encourage you to read the full article.